Representatives from seven US states (Oregon, Nebraska, Michigan, Arizona, Texas, Minnesota, and Pennsylvania) have submitted a letter urging the Drug Enforcement Administration (DEA) to allow terminally-ill patients access to psilocybin treatments. The lawmakers believe that psilocybin qualifies as an investigational drug and should therefore be accessible through Right to Try laws.
“We have a crisis of loneliness and isolation.” Is group psychedelic therapy the solution?
This week, the Institute for Integrative Therapies (IIT) in Minnesota began offering ketamine-assisted therapy in group settings, and will soon offer group therapy with psilocybin and MDMA too.
Group sessions can provide a powerful healing experience and a sense of connection, plus they’re much cheaper than one-on-one sessions at just $500 per person for a 3-hour experience.
Participants work with a therapist both individually and in group settings to prepare for the experience before laying on a floor mat and tripping in a room full of strangers. Each group has a focus such as depression, anxiety, PTSD, existential crises, grief, end of life distress, and LGBTQ experiences.
